BOSTON, Nov. 6, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that its Board of Directors has authorized the repurchase of up to $2 billion worth of PTC common stock through September 30, 2027."This repurchase authorization demonstrates the Board's confidence in PTC's ability to drive customer value while enhancing shareholder returns, and supports PTC's capital allocation strategy," said Janice Chaffin, Chair of the Board."PTC intends to repurchase approximately $300 million of our common stock in ...

EX 99.1 PTC ANNOUNCES FOURTH FISCAL QUARTER AND FULL FISCAL YEAR 2024 RESULTS Solid ARR and Cash Flow in Fourth Fiscal Quarter and Full Fiscal Year BOSTON, MA, November 6, 2024 - PTC (NASDAQ: PTC) today reported financial results for its fourth fiscal quarter and full fiscal year ended September 30, 2024. "In fiscal year 2024, we again delivered solid ARR and cash flow, with year-over-year ARR growth in the low double-digits and cash flow growth above 20%. We have a differentiated strategy that leverages ou ...

PTC Inc. (PTC) is scheduled to report fourth-quarter fiscal 2024 results on Nov. 6.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.For the quarter, PTC anticipates revenues to be between $598 million and $648 million. Non-GAAP earnings per share (EPS) are expected to be between $1.30 and $1.66.The Zacks Consensus Estimate for revenues is pegged at $620.5 million, indicating an increase of 13.5% from the year-ago reported number. The consensus estimate for earnings is pegged at $1.43 ...

Wall Street analysts forecast that PTC Inc. (PTC) will report quarterly earnings of $1.43 per share in its upcoming release, pointing to a year-over-year increase of 19.2%. It is anticipated that revenues will amount to $620.49 million, exhibiting an increase of 13.5% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed ...

Wall Street expects a year-over-year increase in earnings on higher revenues when PTC Inc. (PTC) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on November 6, 2024, might help the stock move higher if these key numbers are better than ex ...

MALVERN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc. (NYSE: VSH) today introduced a new series of inrush current limiting positive temperature coefficient (PTC) thermistors. Designed to increase performance in active charge and discharge circuits for automotive and industrial applications, Vishay BCcomponents PTCEL High Energy series devices combine maximum energy handling to 340 J — five times higher than competing devices at high ambient temperatures — with a wide range of resistan ...

WARREN, N.J., Oct. 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). "The NDA acceptance for review is a significant milestone that brings us one step closer to providing this important treatment to boys and young men living with nonsense mutation Duchenne musc ...

WARREN, N.J., Oct. 24, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, Nov. 7, at 4:30 p.m. EST.To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of ...

Core Insights - PTC Therapeutics, Inc. announced that the FDA has set a target regulatory action date of July 29, 2025, for the review of the New Drug Application (NDA) for sepiapterin, aimed at treating phenylketonuria (PKU) in both pediatric and adult patients [1][3] - The results of the Phase 3 APHENITY trial have been published in The Lancet, highlighting the promising data regarding sepiapterin's potential to address significant unmet medical needs for PKU patients [2][3] Drug Development and Mechanism - Sepiapterin (formerly PTC923) is an oral formulation that acts through a dual mechanism: it serves as a precursor to tetrahydrobiopterin (BH4), enhancing the activity of the phenylalanine hydroxylase (PAH) enzyme, and it also functions as a pharmacological chaperone to correct PAH misfolding [4] - The NDA for sepiapterin includes data from the Phase 3 APHENITY trial and ongoing open-label extension studies, demonstrating that approximately 60% of subjects can achieve protein intake above the recommended daily allowance while maintaining phenylalanine levels below 360 μmol/L [3][4] Disease Overview - Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by a defect in the gene responsible for producing the enzyme that breaks down phenylalanine, leading to severe disabilities if untreated [5] - There are an estimated 58,000 individuals with PKU globally, and early diagnosis is typically conducted through newborn screening programs [5] Company Background - PTC Therapeutics is a global biopharmaceutical company focused on developing and commercializing differentiated medicines for rare disorders, aiming to provide access to effective treatments for patients with limited options [6] - The company's strategy emphasizes leveraging scientific expertise and a global commercial infrastructure to maximize value for stakeholders [6]

- Statistically significant results on primary endpoint of long-term study analyses - - Following FDA pre-NDA feedback, submission on track for December 2024 - WARREN, N.J., Oct. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) provided today several positive updates on the vatiquinone Friedreich ataxia (FA) program. The pre-specified endpoint for two different FA long-term extension studies was met, with highly statistically significant evidence of durable treatment benefit on disease progress ...